American International Group Inc. decreased its position in Progyny, Inc. (NASDAQ:PGNY) by 2.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,523 shares of the company’s stock after selling 445 shares during the period. American International Group Inc.’s holdings in Progyny were worth $658,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in PGNY. US Bancorp DE acquired a new stake in shares of Progyny during the 4th quarter worth approximately $30,000. Parallel Advisors LLC boosted its stake in Progyny by 89.5% during the fourth quarter. Parallel Advisors LLC now owns 978 shares of the company’s stock worth $41,000 after buying an additional 462 shares in the last quarter. Capstone Triton Financial Group LLC acquired a new stake in Progyny during the fourth quarter worth $47,000. Harvard Management Co. Inc. bought a new stake in Progyny in the 4th quarter valued at $159,000. Finally, Victory Capital Management Inc. acquired a new position in shares of Progyny in the 3rd quarter valued at $201,000. Institutional investors own 58.54% of the company’s stock.
NASDAQ PGNY opened at $44.87 on Thursday. Progyny, Inc. has a 1-year low of $17.90 and a 1-year high of $53.48. The company has a 50 day moving average of $46.21 and a 200-day moving average of $39.10. The firm has a market cap of $3.91 billion, a price-to-earnings ratio of 407.91 and a beta of 1.83.
Several research analysts recently issued reports on PGNY shares. Bank of America raised shares of Progyny from a “neutral” rating to a “buy” rating in a research report on Tuesday, March 16th. Zacks Investment Research downgraded Progyny from a “hold” rating to a “sell” rating in a research report on Saturday, February 27th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $37.71.
In other Progyny news, COO Peter Anevski sold 21,000 shares of the stock in a transaction on Monday, February 1st. The stock was sold at an average price of $47.93, for a total value of $1,006,530.00. Following the transaction, the chief operating officer now directly owns 666,146 shares in the company, valued at approximately $31,928,377.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David J. Schlanger sold 112,020 shares of Progyny stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $46.10, for a total value of $5,164,122.00. Insiders sold 421,263 shares of company stock valued at $19,823,422 over the last ninety days. 33.30% of the stock is currently owned by company insiders.
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also: Equity Income
Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY).
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.